Microbiology of airway disease in a cohort of patients with cystic fibrosis.
about
Nasopharyngeal Bacterial Carriage in the Conjugate Vaccine Era with a Focus on PneumococciTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisMatrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients.Sphingobacterium respiratory tract infection in patients with cystic fibrosis.Impact of multidrug-resistant organisms on patients considered for lung transplantation.Outbreak of Corynebacterium pseudodiphtheriticum infection in cystic fibrosis patients, France.Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimensRole of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosisPulmonary exacerbations in cystic fibrosis with negative bacterial cultures.Phenotypic and genotypic properties of Microbacterium yannicii, a recently described multidrug resistant bacterium isolated from a lung transplanted patient with cystic fibrosis in France.Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patientsManagement of refractory Pseudomonas aeruginosa infection in cystic fibrosisWhole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France.Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy.Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degreesDiscrepancy in MALDI-TOF MS identification of uncommon Gram-negative bacteria from lower respiratory secretions in patients with cystic fibrosisCheating fosters species co-existence in well-mixed bacterial communities.Population Dynamics of Patients with Bacterial Resistance in Hospital Environment.Cyanide Toxicity to Burkholderia cenocepacia Is Modulated by Polymicrobial Communities and Environmental FactorsPotential role of high-mobility group box 1 in cystic fibrosis airway disease.Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains.Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Inhaled antibiotics for gram-negative respiratory infections.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Emerging drugs for cystic fibrosis.New perspectives in the management of Pseudomonas aeruginosa infections.Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung.Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis.Modeling the response of a biofilm to silver-based antimicrobial.Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis.Nanoparticle deposition onto biofilms.Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of Pseudomonas aeruginosa infection in cystic fibrosis patients.Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.Discriminating typical and atypical cystic fibrosis-related bacteria by multiplex PNA-FISH.
P2860
Q26782298-1119A5A4-BDE4-4DA8-B4D7-EFBC34F2DD0CQ26829604-E98260D2-C1BC-44AE-A4C0-B1018790371EQ33358344-5016B68D-D4B8-4979-8C90-9927711F19D8Q33520547-5D65DAD6-40ED-46AD-8377-F38A26136EA4Q33576059-D3E333C9-B86A-42B1-99F3-37E19D1EE656Q33647480-36B2C462-A8E5-4A1D-9BC8-1A2489E077A5Q33769610-A944EA3A-1AF9-40BF-ACBC-E0BA6510F3FCQ33770039-05054E8F-0C30-46FB-A7B1-4170C9D1A7AAQ33877139-1D784D52-FA0A-4193-AB63-CC81123DD5D1Q34118967-DC214A39-6399-41AA-B520-6DC49D9C0DF0Q34705295-A1FF8C7E-0D91-4BF9-85B1-12EAD17F540DQ34746975-30DCF3FF-8FF3-4558-9E8C-EC938F92E104Q35026630-FC801FED-B730-4417-84FE-AF713F14FF5DQ35076797-FB630969-60B1-4F71-99AE-E36C112B37A8Q35094033-764C9F37-6916-4E2D-9C42-95D3A1E4E4A3Q35124580-1E5A2FF2-28A0-4376-80E7-B5770F54711CQ35199103-E80B9F56-7E89-4224-BEFF-4E0A83FF6B00Q35586538-C04D7918-468B-4AC8-B728-D534AA1A33EDQ36242295-9E925D05-398C-48D8-9BB2-A4573E0D5D4DQ36556314-BAAA48D3-E9CE-4D8E-92C3-13F2AC6060ECQ36909659-037C9D9A-E944-4C2F-9562-5CEE9EC8CF09Q36935244-C7068159-F108-4424-A373-EAB68290397EQ37695294-1DA67B92-7368-441E-AFD2-B5BA5C6BF084Q37713415-F04C3B43-4539-443A-804D-8996CBB1F6DEQ37775620-56B3935E-8C84-4E57-AC37-9F84500E904EQ37937558-0F961830-1392-43CD-A4AA-4577C5E953C5Q37940005-99A07CE8-AF92-4D62-A98C-A307ABCC4A31Q38183476-4409073B-32C0-4DCD-A423-C9FE61C989A2Q38243221-36F71EEA-FF51-485F-AD62-34866020E560Q38476154-DF1B8651-D5B9-4D6A-8CBF-683A28E2E129Q39218303-C893E176-E13B-4011-8152-F2F4E83BA2B1Q40062783-AFF44B0F-A55D-4DDF-94DA-42EA6FB92FE1Q40420487-A8335CA0-369C-46AF-A0D7-279D503A5858Q41452140-48A7BB12-B9A0-4484-B277-6B6FEE3D3E70Q42121389-80106804-1803-4CBF-B794-A787468FE1ADQ42414603-19D12D0E-B666-4AAE-A963-9A6D07EE17DEQ42584844-A4DDF896-DE23-4E20-945C-5D939B0B2826Q43055018-3FE4E362-0A6A-48ED-ABDB-56FB5ED10EA0Q46297898-06CE21FF-C46D-4E45-ACB9-9E9DA73531FEQ46495945-B7698470-0F9B-4932-ACCD-F813F3B4A540
P2860
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Microbiology of airway disease in a cohort of patients with cystic fibrosis
@nl
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@ast
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@en
type
label
Microbiology of airway disease in a cohort of patients with cystic fibrosis
@nl
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@ast
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@en
prefLabel
Microbiology of airway disease in a cohort of patients with cystic fibrosis
@nl
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@ast
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@en
P2093
P2860
P3181
P356
P1476
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
@en
P2093
Angela Sepe
Antonietta Lambiase
Fabio Rossano
Mariassunta Del Pezzo
Valeria Raia
Vincenzo Carnovale
P2860
P2888
P3181
P356
10.1186/1471-2334-6-4
P407
P577
2006-01-11T00:00:00Z
P5875
P6179
1012323110